How We Should Rethink the Role of Technical Expertise in GMO Regulation
By Dhvani Mehta and Yashaswini Mittal,
The Wire
| 08. 31. 2015
[India]
On August 24, it was reported that the former Union Agriculture Minister, Sharad Pawar, had written to the Prime Minister recommending that he intervene to remove an existing rule that requires a no-objection certificate (NOC) from the relevant state government before field trials for genetically modified (GM) crops may be permitted. Pawar argued that the requirement of obtaining consent from state governments had become a “socio-political process rather than an objective, science-based process of rigorous evaluation at the state level” (emphasis added).
Whether or not one sides with Pawar’s view that the regulatory regime on GM crops ought to be eased, there are two fundamental problems with the statement that he offers in justification. The first assumes that the influence of social and political factors on a decision-making process that will have an impact on thousands of livelihoods and the natural environment is somehow inappropriate and undesirable. The second, which is a corollary of the first, is an unshakeable belief in the ability of science to be neutral and to guide us to the ‘correct’ decision.
Pawar is not the...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...